NCI’s Antibody Characterization Program is seeking cancer-related protein targets for antibody development. Submissions due on or before July 9, 2012.

The National Cancer Institute (NCI), part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium (CPTAC) in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. Read more.
April 16, 2012
April 12, 2012
February 24, 2012
February 08, 2012
August 22, 2011
The Antibody Portal serves as a public resource of monoclonal antibodies made available by the NCI for the scientific community to support protein/peptide measurement and analysis efforts.